Abstract:e19014 Background: Pemetrexed has been approved for ﬁrst- and second-line treatment in patients with non-small cell lung cancer (NSCLC). Two studies have confirmed the role of polymorphisms (SNPs) in reduced folate carrier (SLC19A1) is related with the survival differences in pemetrexed-treated NSCLC in Caucasian population. Considering different genetic backgrounds in different populations, our study was aimed to identify candidate SNPs for pemetrexed-treated NSCLC in Chinese Han population. Methods: Fifty-seven patients with previously treated NSCLC received pemetrexed-based third-line treatment from Shanghai Chest Hospital from Nov 2006 to Jul 2011. Four genes, SLC19A1, gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR), and methionine synthase (MTR), responsible for pemetrexed transport and activation were evaluated. The five SNPs (rs4819128, rs914232, rs4818789, rs3788189, rs1051298) in SLC19A1, two SNPs (rs3780130, rs3780126) in GGH, two SNPs (rs1801133, rs180131) in MTHER, and one SNP (rs1805087) in MTR were selected based on the HapMap Chinese Han databases. All SNP genotyping was performed by TaqMan PCR using the ABI Prism 7900HT Sequence Detection System. Kaplan-Meier cumulative probability and Cox multivariate analyses were used to evaluate the relationship between genetic variations with survival outcome. Results: Fifty-seven patients received a median of three cycles (range, 1-16 cycles) of pemetrexed-based treatment. Median overall survival (OS) and progression-free survival (PFS) times were 23.0 and 3.2 months, respectively. Patients with AA/AG genotype of SLC19A1 rs1051298 had the better PFS and OS compared with GG genotype (5.5m vs 1.9m for PFS, P=0.047; 45.5m vs 17m for OS, P=0.001). The TT/TA genotype of novel GGH rs3780130 was correlated with better PFS compared with AA genotype (5.8m vs 2.5m, P=0.029). Conclusions: This study in Chinese Han NSCLC patients identified the unique result that novel TT/TA genotype of GGH rs3780130 was related with better PFS for pemetrexed-based treatment. Meanwhile, we obtained the same result with that in Caucasian study, AA/AG genotype of SLC19A1 rs1051298 was related with better PFS and OS.

Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer

Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine

Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non-small cell lung cancer.

Genetic Variants in One‐carbon Metabolism‐related Genes Contribute to NSCLC Prognosis in a Chinese Population

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Methylenetetrahydrofolate Reductase C677T Polymorphism Predicts Response and Time to Progression to Gemcitabine-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Chinese Han Population

Genetic variations in <i>SLC3A2/CD98</i> gene as prognosis predictors in non‐small cell lung cancer

Genetic Variants of BCL2 Gene Predict Clinical Outcomes of Non-Small-cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy in a Chinese Population.

Genetic Variations in Genes of Metabolic Enzymes Predict Postoperational Prognosis of Patients with Colorectal Cancer

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients.

Associations Of Polymorphisms In Dna Repair Genes And Mdr1 Gene With Chemotherapy Response And Survival Of Non-Small Cell Lung Cancer

The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients.

Genetic Variants Of Nbs1 Predict Clinical Outcome Of Platinum-Based Chemotherapy In Advanced Non-Small Cell Lung Cancer In Chinese

Associations of genetic polymorphisms of the transporters organic cation transporter 2 ( OCT2 ), multidrug and toxin extrusion 1 ( MATE1 ), and ATP-binding cassette subfamily C member 2 ( ABCC2 ) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients

MicroRNA-Related Genetic Variants As Predictors of Early Stage Non–Small Cell Lung Cancer Clinical Outcomes

A Pemetrexed-Based Genetic Study of Chinese Han Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).